The Company intends to use these specific funds to study the use of adult stem cells from human adipose tissue for bone repair and for hematopoietic
support in bone marrow transplantation.
Since the first close of our Series B, Cellerant has made significant progress in advancing our purified hematopoietic
stem cell infusion, CLT-001, toward the clinic for sickle cell disease.
Pluristem's core technology is designed to expand Hematopoietic
Stem Cells (HSC).
5,061,620) for the separation of human hematopoietic
stem cells from bone marrow and for their cellular composition.
Until now the field of bone marrow transplantation has been limited to procedures and technologies that expand hematopoietic
stem cells only.
Critical shortfall in the supply of matched tissue for transplantation creates an urgent need for alternative sources of hematopoietic
stem cells (HSCs).
Chairman Max Link said, "This is the first of, we hope, many collaborations we will establish with our new partner and complements our already extensive R&D portfolio of hematopoietic
growth factors, which includes granulocyte-macrophoge colony stimulating factor (GM-CSF), Interleukin 3 (IL-3), Interleukin 6 (IL-6) and Leukemia Inhibitory Factor (LIF).
Zami Aberman, CEO, stated: "Pluristem's novel approach has literally reinvented the field of bone marrow transplantation which until now has been limited to procedures and technologies that expand hematopoietic
stem cells only.
In the March 15 issue of Blood, SyStemix scientists reported new data supporting that the company's proprietary SCID-hu mouse provides a useful and unique preclinical model to assess the in vivo effects of human hematopoietic
growth factors as novel therapeutics for the human blood forming system, otherwise known as the hematopoietic
to form a 50/50 joint venture whose primary mission will be to research and develop hematopoietic
cell-based, somatic gene therapies against HIV infection.
based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic
stem cells, human megakaryocytes and megakaryocyte progenitors.
The companies' other collaboration, in therapeutic antiviral agents for HIV infection, and their partnership, Progenesys, in hematopoietic
cell-based, somatic gene therapies against HIV infection, are unaffected.